OnKure Therapeutics, Inc.
Tremor tracks 1 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Sep 21, 2026+5.9
Trials
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
4 sales (4 not pre-planned) · 0 purchases
- Saccomano Nicholas APresident and CEO · Sep 21, 2026Sold 87 sharesabout $259 · not pre-planned
- Leverone Jason A.Chief Financial Officer · Sep 21, 2026Sold 302 sharesabout $898 · not pre-planned
- Saccomano Nicholas APresident and CEO · Jun 22, 2026Sold 86 sharesabout $378 · not pre-planned
- Leverone Jason A.Chief Financial Officer · Jun 22, 2026Sold 303 sharesabout $1 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.